Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
PMID: 19537723
2009
Journal of chemical information and modeling
Abstract: Interestingly, in atazanavir complexes, in the presence of the L76V substitution, the drug revealed a more productive binding affinity, in agreement with hypersusceptibility data.
Combating HIV resistance - focus on darunavir.
PMID: 19209258
2008
Therapeutics and clinical risk management
Abstract: Darunavir resistance-associated mutations have been defined as V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V.
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
PMID: 18765410
2008
The Journal of antimicrobial chemotherapy
Abstract: The I437T/V mutation in gag and the L76V mutation in the protease were associated with a lower risk of selecting darunavir resistance mutations.
Abstract: There was an association between the presence of the mutation A431V in the gag sequence and the selection of the L76V mutation in the protease sequence in the latest available rebound.
Abstract: Virus with L76V in protease or I437T/V in gag may be already resistant to darunavir and, therefore, no additional resistance mutations need to be selected.
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
Abstract: Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance.
Abstract: Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
PMID: 18039922
2008
Antimicrobial agents and chemotherapy
Abstract: By contrast, L76V, a known DRV resistance mutation, was found to decrease the risk of selection of another DRV resistance mutation.
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
PMID: 17646201
2007
The Journal of antimicrobial chemotherapy
Abstract: The prevalence of major darunavir resistance mutations was I50V 2.1%, I54M 1.3%, L76V 2.7% and I84V 14.5%.
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
Result: Finally, the lower-left part of the figure contains a cluster with seven of the 11 mutations recently reported to be associated with phenotypic and clinical resistance to the newest PI, darunavir (V32I, Discussion: Protease covariation was dominated by the clustering of nelfinavir-associated mutations (D30N and N88D), two main groups of PI-resistance mutations associated either with V82A or L90M, and a newly identified cluster of the mutations V32I, L33F, I47V, I50V, I54L/M, and L76V.
HIV mutation literature information.
PMID: 
2009
Journal of chemical information and modeling
Browser Board
Co-occurred Entities
Filtrator
ViMRT